U.S. flag

An official website of the United States government

NM_000152.5(GAA):c.132C>T (p.Gly44=) AND Glycogen storage disease, type II

Germline classification:
Likely benign (1 submission)
Last evaluated:
Jun 29, 2023
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV001496435.7

Allele description [Variation Report for NM_000152.5(GAA):c.132C>T (p.Gly44=)]

NM_000152.5(GAA):c.132C>T (p.Gly44=)

Gene:
GAA:alpha glucosidase [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
17q25.3
Genomic location:
Preferred name:
NM_000152.5(GAA):c.132C>T (p.Gly44=)
HGVS:
  • NC_000017.11:g.80104718C>T
  • NG_009822.1:g.8163C>T
  • NM_000152.5:c.132C>TMANE SELECT
  • NM_001079803.3:c.132C>T
  • NM_001079804.3:c.132C>T
  • NP_000143.2:p.Gly44=
  • NP_001073271.1:p.Gly44=
  • NP_001073272.1:p.Gly44=
  • LRG_673:g.8163C>T
  • NC_000017.10:g.78078517C>T
Links:
dbSNP: rs2143825106
NCBI 1000 Genomes Browser:
rs2143825106
Molecular consequence:
  • NM_000152.5:c.132C>T - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001079803.3:c.132C>T - synonymous variant - [Sequence Ontology: SO:0001819]
  • NM_001079804.3:c.132C>T - synonymous variant - [Sequence Ontology: SO:0001819]

Condition(s)

Name:
Glycogen storage disease, type II (GSD2)
Synonyms:
ACID ALPHA-GLUCOSIDASE DEFICIENCY; GLYCOGENOSIS, GENERALIZED, CARDIAC FORM; GSD II; See all synonyms [MedGen]
Identifiers:
MONDO: MONDO:0009290; MedGen: C0017921; Orphanet: 365; OMIM: 232300

Recent activity

Clear Turn Off Turn On
  • Trimethoprim, Sulfamethoxazole Drug Combination
    Trimethoprim, Sulfamethoxazole Drug Combination
    A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, incl...<br/>Year introduced: 2016 (1990)
    MeSH

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV001701134Labcorp Genetics (formerly Invitae), Labcorp
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))		Likely benign
(Jun 29, 2023) 		germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV001701134.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Sep 29, 2024